Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01811693 · ClinicalTrials.gov registry record · Phase 2
Field Administration of Stroke Therapy-Blood Pressure Lowering
A Phase 2 study, sponsored by University of California, Los Angeles.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT01811693 is a Phase 2 study that was terminated before completion, run by University of California, Los Angeles. The registered enrollment target is 4 participants.
The verdict
NCT01811693, a Phase 2 study, was terminated before completion, sponsored by University of California, Los Angeles.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
This is an open, pilot, dose-escalation study of glyceryl trinitrate (GTN, Nitroglycerin) administered by paramedics in the field within 2 hours of symptom onset to 45 severely hypertensive stroke patients. The primary objective of the study is to evaluate the feasibility, safety, and physiologic efficacy of field-initiated glyceryl trinitrate in achieving modest reduction of blood pressure. Patients with acute stroke will be identified in the field by paramedics who have received training in basic and advanced cardiac life support, stroke recognition, and specific procedures relevant to the proposed study. Physician-investigators will obtain informed consent for each subject for study entry after cellular phone contact with paramedics. Paramedics will initiate antihypertensive treatment by applying transdermal GTN patch in the first two dose-tiers, and administering a single sublingual GTN metered spray followed by application of the transdermal system in the last dose tier. The sites involved in the study will be emergency medical services rescue ambulances and 8 receiving Stroke Center hospitals in Orange County, California, USA.
Interventions
- DRUG Glycerly Trinitrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2013-04 |
| Est. Completion | 2013-12-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01811693
The ClinicalTrials.gov registry entry for NCT01811693 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Glycerly Trinitrate is the first listed.
NCT01811693 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01811693 about?
NCT01811693 is a clinical study titled "Field Administration of Stroke Therapy-Blood Pressure Lowering". This is an open, pilot, dose-escalation study of glyceryl trinitrate (GTN, Nitroglycerin) administered by paramedics in the field within 2 hours of symptom onset to 45 severely hypertensive stroke patients. The primary objective of the study is to evaluate the feasibility, safety, and physiologic ef...
What is the current status of trial NCT01811693?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2013-04. Estimated completion is 2013-12-09.
What interventions are being tested in trial NCT01811693?
The interventions under investigation include: Glycerly Trinitrate (DRUG).
Who is sponsoring clinical trial NCT01811693?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.